Abstract
There are at present no antivirals available which have been formally licensed for clinical use for the treatment of Ebola virus (EBOV) infections in humans. The most advanced to be approved for this purpose is favipiravir (T-705), a viral RNA polymerase inhibitor. Under consideration are BCX4430, also a viral RNA polymerase inhibitor, and 3-deazaneplanocin A and various other S-adenosylhomocysteine (SAH) hydrolase inhibitors. A number of compounds which have been approved for other purposes seem to interact with the cell entry of EBOV. Some compounds like pyrazofurin have been found to be exquisitely potent inhibitors of vesicular stomatitis virus (VSV). VSV belongs to the rhabdoviridae, a family closely related to the family of the filoviridae to which EBOV and Marburg virus belong. VSV, unlike EBOV and Marburg virus which require biosafety level 4, can be handled in conventional safety conditions. Key words: Ebola virus (EBOV); vesicular stomatitis virus (VSV); rhabdoviridae; filoviridae; favipiravir; BCX4430; pyrazofurin; SAH hydrolase
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
